resTORbio (NASDAQ:TORC) released its quarterly earnings results on Thursday. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.06), Bloomberg Earnings reports.
NASDAQ:TORC traded down $0.01 during midday trading on Friday, hitting $11.32. 166,190 shares of the stock were exchanged, compared to its average volume of 714,400. resTORbio has a one year low of $7.55 and a one year high of $21.10. The stock has a market cap of $334.87 million and a price-to-earnings ratio of -1.34.
A number of equities research analysts have recently weighed in on the company. Evercore ISI reaffirmed an “in-line” rating on shares of resTORbio in a report on Wednesday, August 1st. ValuEngine raised resTORbio from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research raised resTORbio from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Tuesday, July 31st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $26.60.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.